Want to see AORT full AI Analyst Report?
AORT Stock Chart & Stats
$37.72
$0.30(1.03%)
At close: 4:00 PM EST
$37.72
$0.30(1.03%)
Day’s Range― - ―
52-Week Range$19.16 - $48.25
Previous CloseN/A
Volume97.41K
Average Volume (3M)778.65K
Market Cap
$1.23B
Enterprise Value$2.02K
Total Cash (Recent Filing)$55.76M
Total Debt (Recent Filing)$258.16M
Price to Earnings (P/E)101.2
Beta0.69
Next Earnings
Jul 30, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.25
Shares Outstanding48,543,350
10 Day Avg. Volume513,183
30 Day Avg. Volume778,647
Financial Highlights & Ratios
PEG Ratio-1.23
Price to Book (P/B)4.61
Price to Sales (P/S)4.69
P/FCF Ratio-2.27K
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$42.67Price Target Upside13.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.08
Revenue Forecast (FY)$486.23M
Bulls Say, Bears Say
Bulls Say
Steady Revenue Growth & ProfitabilityArtivion’s multi-year top-line growth and return to net profitability signal durable demand for its vascular and tissue products. Sustained revenue expansion and positive earnings provide capacity to reinvest in R&D, support commercialization of new platforms, and absorb near-term shocks without structural solvency risk.
Improved Balance Sheet & DeleveragingMaterial deleveraging and a larger equity base increase financial flexibility to fund launches and M&A. Lower leverage reduces refinancing and distress risk, enabling the company to pursue strategic investments like Endospan while maintaining capacity to withstand cyclical procedure-volume swings.
Strategic Acquisition & FDA PMA For NEXUSOwning the NEXUS platform and Endospan pipeline materially expands Artivion’s addressable market in aortic arch solutions. The combined portfolio and planned U.S. launch create structural competitive differentiation and multi-year revenue upside if commercial execution converts PMA approval into adoption across treating centers.
Bears Say
Thin Margins & Volatile Free Cash FlowPersistently low net margins and inconsistent free cash flow constrain internal funding for growth and make returns on capital modest. This structural margin pressure increases sensitivity to reimbursement or volume shocks and limits the pace at which the firm can sustainably scale commercialization without external financing.
Acquisition-related Earnings Pressure & Higher InterestFinancing the Endospan deal raises ongoing interest costs and near‑term EBITDA dilution from integration and launch expenses. Elevated interest and acquisition burden reduce free cash available for organic initiatives and heighten earnings volatility until synergies and revenue from NEXUS materialize.
Commercial Execution & Supply RisksAdoption timing delays (AMDS starter sets), regional distributor variability, and isolated supply-chain issues create recurring execution risk. These structural go‑to‑market and operational challenges can delay revenue realization from new products and extend the timeline for converting regulatory wins into sustained commercial growth.
AORT FAQ
What was Artivion Inc.’s price range in the past 12 months?
Artivion Inc. lowest stock price was $19.16 and its highest was $48.25 in the past 12 months.
What is Artivion Inc.’s market cap?
Artivion Inc.’s market cap is $1.23B.
When is Artivion Inc.’s upcoming earnings report date?
Artivion Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 7 days.
How were Artivion Inc.’s earnings last quarter?
Artivion Inc. released its earnings results on May 07, 2026. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of $0.026 by $0.004.
Is Artivion Inc. overvalued?
According to Wall Street analysts Artivion Inc.’s price is currently Undervalued.
Does Artivion Inc. pay dividends?
Artivion Inc. pays a Quarterly dividend of $0.03 which represents an annual dividend yield of N/A. See more information on Artivion Inc. dividends here
What is Artivion Inc.’s EPS estimate?
Artivion Inc.’s EPS estimate is <0.01.
How many shares outstanding does Artivion Inc. have?
Artivion Inc. has 48,543,350 shares outstanding.
What happened to Artivion Inc.’s price movement after its last earnings report?
Artivion Inc. reported an EPS of $0.03 in its last earnings report, beating expectations of $0.026. Following the earnings report the stock price went down -28.261%.
Which hedge fund is a major shareholder of Artivion Inc.?
Currently, no hedge funds are holding shares in AORT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Artivion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.67 (13.11% Upside)
$42.67 (13.11% Upside)
Blogger Sentiment
Bullish
AORT Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 598.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.60%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
11.63%
Trailing 12-Months
Company Description
Artivion Inc.
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
AORT Stock 12 Month Forecast
Average Price Target
$42.67
▲(13.11% Upside)
Technical Analysis
Ownership Overview
5.28% Insiders
33.45% Mutual Funds
<0.01% Other Institutional Investors
40.20% Public Companies and
Individual Investors









